Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis

J. Maurice Hourihane, Thomas Deloughery, Wayne Clark

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The factor V Leiden mutation is a specific point mutation in the gene coding for factor V. It renders activated factor V resistant to degradation by activated protein C (APC). This hereditary resistance to APC (HRAPC) is a known risk factor for systemic venous thrombosis. We present a case of homozygous HRAPC presenting as cerebral venous thrombosis (CVT). A 24-year-old woman presented with a dense left hemiplegia and papiledema. A computed tomography scan showed a high ritht parieto-occipital infarct with hemorrhagic conversion. Angiography confirmed the diagnosis of extensive CVT. Treatment included heparin and direct intrathrombus thrombolysis initially as a bolus and then as an infusion for 21 hours. Repeat angiography showed partial recanalization. After 9 days, the patient was discharged on warfarin with minimal residual left weakness but persistent papilledema. Homozygous HRAPC appears to be a risk factor for CVT and should be considered in the evaluation of CVT.

Original languageEnglish (US)
Pages (from-to)370-372
Number of pages3
JournalJournal of Stroke and Cerebrovascular Diseases
Volume6
Issue number5
DOIs
StatePublished - Jul 1997

Fingerprint

Intracranial Thrombosis
Venous Thrombosis
Activated Protein C Resistance
Angiography
Factor Va
Papilledema
Hemiplegia
Factor V
Warfarin
Protein C
Point Mutation
Heparin
Tomography
Thrombophilia due to Activated Protein C Resistance
Mutation
Genes

Keywords

  • APC
  • Cerebral venous thrombosis
  • HRAPC

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis. / Hourihane, J. Maurice; Deloughery, Thomas; Clark, Wayne.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 6, No. 5, 07.1997, p. 370-372.

Research output: Contribution to journalArticle

@article{42d11a2b058b457bb2adba03b0865ccb,
title = "Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis",
abstract = "The factor V Leiden mutation is a specific point mutation in the gene coding for factor V. It renders activated factor V resistant to degradation by activated protein C (APC). This hereditary resistance to APC (HRAPC) is a known risk factor for systemic venous thrombosis. We present a case of homozygous HRAPC presenting as cerebral venous thrombosis (CVT). A 24-year-old woman presented with a dense left hemiplegia and papiledema. A computed tomography scan showed a high ritht parieto-occipital infarct with hemorrhagic conversion. Angiography confirmed the diagnosis of extensive CVT. Treatment included heparin and direct intrathrombus thrombolysis initially as a bolus and then as an infusion for 21 hours. Repeat angiography showed partial recanalization. After 9 days, the patient was discharged on warfarin with minimal residual left weakness but persistent papilledema. Homozygous HRAPC appears to be a risk factor for CVT and should be considered in the evaluation of CVT.",
keywords = "APC, Cerebral venous thrombosis, HRAPC",
author = "Hourihane, {J. Maurice} and Thomas Deloughery and Wayne Clark",
year = "1997",
month = "7",
doi = "10.1016/S1052-3057(97)80221-2",
language = "English (US)",
volume = "6",
pages = "370--372",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis

AU - Hourihane, J. Maurice

AU - Deloughery, Thomas

AU - Clark, Wayne

PY - 1997/7

Y1 - 1997/7

N2 - The factor V Leiden mutation is a specific point mutation in the gene coding for factor V. It renders activated factor V resistant to degradation by activated protein C (APC). This hereditary resistance to APC (HRAPC) is a known risk factor for systemic venous thrombosis. We present a case of homozygous HRAPC presenting as cerebral venous thrombosis (CVT). A 24-year-old woman presented with a dense left hemiplegia and papiledema. A computed tomography scan showed a high ritht parieto-occipital infarct with hemorrhagic conversion. Angiography confirmed the diagnosis of extensive CVT. Treatment included heparin and direct intrathrombus thrombolysis initially as a bolus and then as an infusion for 21 hours. Repeat angiography showed partial recanalization. After 9 days, the patient was discharged on warfarin with minimal residual left weakness but persistent papilledema. Homozygous HRAPC appears to be a risk factor for CVT and should be considered in the evaluation of CVT.

AB - The factor V Leiden mutation is a specific point mutation in the gene coding for factor V. It renders activated factor V resistant to degradation by activated protein C (APC). This hereditary resistance to APC (HRAPC) is a known risk factor for systemic venous thrombosis. We present a case of homozygous HRAPC presenting as cerebral venous thrombosis (CVT). A 24-year-old woman presented with a dense left hemiplegia and papiledema. A computed tomography scan showed a high ritht parieto-occipital infarct with hemorrhagic conversion. Angiography confirmed the diagnosis of extensive CVT. Treatment included heparin and direct intrathrombus thrombolysis initially as a bolus and then as an infusion for 21 hours. Repeat angiography showed partial recanalization. After 9 days, the patient was discharged on warfarin with minimal residual left weakness but persistent papilledema. Homozygous HRAPC appears to be a risk factor for CVT and should be considered in the evaluation of CVT.

KW - APC

KW - Cerebral venous thrombosis

KW - HRAPC

UR - http://www.scopus.com/inward/record.url?scp=0344951456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344951456&partnerID=8YFLogxK

U2 - 10.1016/S1052-3057(97)80221-2

DO - 10.1016/S1052-3057(97)80221-2

M3 - Article

VL - 6

SP - 370

EP - 372

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 5

ER -